Results showed a greater percentage of povorcitinib-treated patients achieved HiSCR50 compared with placebo at week 12. Topline data were announced from two pivotal phase 3 studies evaluating ...

The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not ...

Treatment for hidradenitis suppurativa (HS ... Many medications can help treat minor to moderate cases of HS. In more severe cases, a doctor may prescribe stronger drugs or recommend a surgical ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The FDA has approved Bimzelx for the treatment of moderate to severe hidradenitis suppurativa in adults, UCB announced in a press release. Genetic variants found in hidradenitis suppurativa may be ...

One key opportunity for growth of the hidradenitis Suppurativa market is the untapped potential found in emerging countries with growing healthcare infrastructure and treatment availability. This ...

Results from the Phase III STOP-HS1 and STOP-HS2 trials show that povorcitinib (Incyte), an oral JAK1 inhibitor, successfully met the primary endpoint in treating moderate to severe hidradenitis ...

with moderate to severe hidradenitis suppurativa (HS). Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion ...

The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high, likely due to ...

with moderate to severe hidradenitis suppurativa (HS). Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin condition characterized by painful, recurrent boil ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.